Data about overall survival seems immature to me, it seems like there is a slight advantage for the sequential therapy, not very significant, but both arms at 36 months are far away from having reached the median. So I think we have to wait for that parameter.
The study enrolled 130 patients with de novo high-volume mHSPC who had initiated androgen deprivation therapy (ADT) within four weeks and had a PSA level greater than 10 ng/ml at diagnosis. Patients underwent PSMA and FDG PET scans to confirm high PSMA uptake and were randomized into two groups:
Experimental Arm: Two cycles of 177Lu-PSMA-617 followed by six cycles of docetaxel.
Control Arm: Six cycles of docetaxel alone.
The primary endpoint was achieving an undetectable PSA level (≤0.2 ng/ml) at 48 weeks. Results showed that 41% of patients in the experimental arm reached this endpoint, compared to 16% in the control arm (odds ratio [OR]: 3.88; p=0.002).
Additionally, the experimental arm demonstrated:
Improved PSA Progression-Free Survival: Median of 31 months versus 20 months (hazard ratio [HR]: 0.60; p=0.039).
Delayed Development of Castration Resistance: HR of 0.60 (p=0.033).
CHAARTED Trial - Long-Term Survival Analysis.
Hi folks, are the Metastatic Hormone Sensitive Prostate Cancer (mHSPC) patients here, which, treatments are at least ADT2, taken Docetaxel?
Management of the Metastases in Oligometastatic Prostate Cancer 
